


# Reagentless Oxidative Folding of Disulfide-Rich Peptides Catalyzed by an Intramolecular Diselenide\*\*

Andrew M. Steiner, Kenneth J. Woycechowsky, Baldomero M. Olivera, and Grzegorz Bulaj\*



Disulfide bonds are critical to stabilizing the native structure of many peptides and proteins. These crosslinks are formed during oxidative folding, and machinery to assist formation of the correct cysteine pairings is used by all walks of life, from prokaryotes to humans.<sup>[1,2]</sup> However, in the chemical synthesis of disulfide-containing biomolecules alternative methods are employed to arrive at the native disulfide connectivity,<sup>[3]</sup> and usually involves redox buffers and requires peptide-specific optimization.<sup>[4]</sup>

Selenocysteine is often referred to as nature's 21st proteinogenic amino acid,<sup>[5]</sup> and it can be readily incorporated into chemically synthesized peptides. Since diselenide bonds have greater thermodynamic stability than disulfide bonds, selenocysteine pairings can prevail over sequence-encoded folding information in short, cysteine-rich peptides.<sup>[6]</sup> By serving as a proxy for a disulfide bridge, selenocysteine incorporation into peptides may reduce the complexity of oxidative folding.<sup>[4,6–9]</sup> Consequently, diselenide bonds in peptides have been assumed to act as a fixed structural element during oxidative folding as a result of their high stability.


Diselenide bridges were incorporated into only a handful of cysteine-rich peptides including two-disulfide-containing apamin<sup>[6,10]</sup> and  $\alpha$  conotoxins,<sup>[7,11]</sup> as well as three-disulfide-bridged conotoxins.<sup>[4,8,12,13]</sup> Diselenides have also been useful to facilitate disulfide mapping.<sup>[12,14]</sup> While several groups have noted the enhanced kinetics of disulfide formation in selenopeptides,<sup>[8,11]</sup> to date, the rate enhancement has been assumed to be due to conformational effects.

Diselenide additives have been found to catalyze oxidative protein folding for a wide range of substrates.<sup>[15,16]</sup> With these additives, catalysis stems from rapid regeneration of the diselenide by reaction of the selenols formed in situ with atmospheric oxygen, even under (mildly) reducing conditions.<sup>[4,8]</sup> In contrast, thiols will not readily oxidize without a catalyst, such as a metal ion. Here we tested a hypothesis that if a diselenide can act as an intermolecular catalyst of cysteine oxidation, then disulfide-rich selenopeptides should be able to catalyze their own aerobic oxidative folding.

Conotoxins, which are derived from the venom of marine gastropods, represent an important target for improvements in oxidative folding efficiency. The venom of each species of

*Conus* has a large and distinct array of disulfide-rich peptides, many of which are used as neuropharmacological tools.<sup>[17]</sup> While conotoxins have broad applicability, their oxidative folding is often quite challenging,<sup>[4,8,11,18,19]</sup> thus making conotoxins an attractive system for studying the mechanisms of oxidative folding.

To examine whether diselenides enable the reagentless oxidative folding of cysteine-rich peptides, we selected previously characterized selenocysteine-containing analogues of  $\omega$ -conotoxin GVIA and  $\mu$ -conotoxin SIIIA (Figure 1).<sup>[4,8]</sup>



**Figure 1.** Folded products of peptides used in this study. a) Three-dimensional structure of GVIA (PDBID: 2CCO). b) Schematic representation of GVIA, where the bridge indicated in green was replaced with a diselenide in [C8U;C19U] GVIA. c) Three-dimensional structure of SIIIA (BMRB #20023). d) Schematic representation of SIIIA; the bridge indicated in green was replaced with selenocysteines in [C4U;C19U] SIIIA. Z = pyrroglutamate, O = hydroxyproline, and # = C-terminal amidation.

Comparisons of the folding behavior for GVIA and [C8U;C19U] GVIA in Tris-buffered water—without any oxidative reagents—are shown in Figures 2a–c. Both  $k_{ox}$  (the rate of formation of the first disulfide) and  $k_{native}$  (the rate of appearance of the native connectivity) show significant enhancement in the presence of a diselenide, thus indicating its role in directing both oxidation and isomerization. To test the generality of this effect, similar experiments were also carried out using  $\mu$ -conotoxin SIIIA and [C4U;C19U] SIIIA (Figures 2d–f). The significant increase in both  $k_{ox}$  (by approximately 12- to 20-fold) and  $k_{native}$  (by approximately 34- to 175-fold) indicated that diselenides are efficient oxidative catalysts independent of the disulfide scaffold. Details of the kinetic analysis are presented in the Supporting Information.

The reagent-free formation of a disulfide bond by an intramolecular diselenide likely involves three chemical processes. First, the diselenide transfers an oxidizing equivalent to a pair of thiols to form a disulfide. Second, the selenol(ate) acts as a nucleophile to promote disulfide isomerization. Third, the selenol(ate)s are reoxidized by molecular oxygen in solution.

Both copper(II) and selenocysteine are known to catalyze the oxidation of thiols to disulfides.<sup>[20,21]</sup> For both disulfide scaffolds considered, the addition of these oxidative catalysts afforded a substantial increase in the rate of oxidation ( $k_{ox}$ ). Similarly, the rate of native formation ( $k_{native}$ ) was also enhanced, albeit to a much lower extent. A discussion of


[\*] A. M. Steiner, Prof. Dr. G. Bulaj  
Department of Medicinal Chemistry, University of Utah  
421 Wakara Way, Suite 360, Salt Lake City, UT 84108 (USA)  
E-mail: bulaj@pharm.utah.edu

Prof. Dr. K. J. Woycechowsky  
Department of Chemistry, University of Utah  
315 S. 1400 E., Rm. 1320, Salt Lake City, UT 84112 (USA)

Prof. Dr. B. M. Olivera  
Department of Biology, University of Utah  
257 S. 1400 E., Rm. 115, Salt Lake City, UT 84112 (USA)

[\*\*] We thank Professors David Blair, David Goldenberg, and Donald Hilvert for helpful discussions and comments on the manuscript. We also acknowledge the assistance of the Peptide Synthesis and Mass Spectrometry Core Facilities at the University of Utah. This work was supported by the NIH Program Project Grant GM 48677.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201200062>.




**Figure 2.** Folding kinetics of GVIA, SIIIA, and their diselenide-containing analogues. HPLC chromatograms after 1 hour of folding for comparison of GVIA (a) and SIIIA (b) to their respective diselenide-containing analogues. R=reduced form, F=natively folded form. Full folding timecourses are available in Figure S4 of the Supporting Information. c,d) Kinetic traces of the disappearance of the starting material (bearing either six thiols or four thiols and a diselenide), with insets showing the depletion of each reduced peptide (maintaining colors) when the all-thiol and diselenide-containing peptides are folded in a 1:1 mixture. e,f) Kinetic traces of the formation of the natively bridged peptide. Equivalent traces using a linear timescale are shown in Figures S2 and S3 of the Supporting Information.

the error values for the rate of native formation ( $k_{\text{native}}$ ) is provided in the Supporting Information. However, for diselenide-containing peptides, neither oxidative catalyst provided a significant change in either the rate of oxidation or the rate of native formation (Figure 3). Interestingly, the folding of wild-type GVIA in the presence of a selenocystine additive remains less efficient than that of reagentless folding with [C8U;C19U] GVIA.

The kinetic advantage of an intramolecular diselenide over added intermolecular diselenide in GVIA suggests a unimolecular mechanism. However, further analysis sug-

gests that the reaction shows both inter- and intramolecular character. On one hand, the initial oxidation of [C8U;C19U] GVIA appears concentration-independent across a 10-fold range in concentrations (see Figure S1 in the Supporting Information). However, a 1:1 mixture of diselenide-containing peptide with its all-thiol counterpart suggests that intermolecular catalysis also contributes (Figures 2b and e, insets). This mixture of inter- and intramolecular catalysis is particularly pronounced for SIIIA, where the initial oxidation step ( $k_{\text{ox}}$ ) was slightly faster with added selenocystine (intermolecular catalysis), but isomerizations and subsequent



**Figure 3.** Rate constant comparison. a) Rate constants for initial oxidation. b) Rate constants for the formation of the native connectivity. On each graph are compared GVIA, GVIA with 100 nM cupric chloride, [C8U;C19U] GVIA with 100 nM cupric chloride, [C8U;C19U] GVIA, GVIA with equimolar selenocysteine, [C8U;C19U] GVIA with equimolar selenocysteine, as well as variation resulting from the location of the diselenide within SIIIA. GVIA and GVIA analogues (white bars) are graphed on the left axis; SIIIA and SIIIA analogues (grey bars) are graphed on the right axis. In all cases,  $n=3$  and values shown are mean  $\pm$  SEM.

oxidations leading to the native disulfide connectivity ( $k_{native}$ ) were slightly faster with an intramolecular diselenide (see Table S1 in the Supporting Information). Further discussion is provided in the Supporting Information.

To consider the role of diselenide placement within a peptide scaffold, we compared [C4U;C19U] SIIIA with [C3U;C13U] SIIIA and [C8U;C20U] SIIIA, which were chosen for this analysis because the reduced and folded forms are more readily separable by HPLC than the comparable analogues of GVIA. This data is shown in Figure 3 and in the Supporting Information (Table S1), and demonstrates that the presence of a diselenide—regardless of its position in the peptide—greatly accelerates folding. While always beneficial,

the position of the diselenide within the peptide does lead to some variation in the folding rate enhancement. This variation could result from either conformation-induced orientation effects or differential stability and activation energies conferred to intermediate conformations by the location of the diselenide bridge.

Thus, in addition to directing oxidative folding towards the native disulfide connectivity, intramolecular diselenide bridges also serve as catalysts for the formation of disulfide bridges. A diselenide bridge in a peptide is therefore able to catalyze disulfide formation using dissolved oxygen as the stoichiometric oxidant, thus effectively enabling reagentless oxidation. Using only molecular oxygen as the oxidant further simplifies the oxidative folding of cysteine-rich peptides. We envision the use of reagentless oxidation of selenopeptides, whether in solution or on-resin<sup>[4]</sup> will be effective, even for peptides that are difficult to synthesize.<sup>[19]</sup>

In the folding of selenopeptides, Se–S bonds are likely to be necessary intermediates for catalysis of intramolecular electron-transfer reactions and isomerization steps. Examples of stable Se–S bonds are rare<sup>[22]</sup> Non-native Se–S bonds have also been shown to exist in synthetic  $\alpha$ conotoxin and oxytocin analogues bearing a native pair of selenocysteines.<sup>[7,11,23]</sup> The high reactivity of selenocysteine is likely the reason why nature has selected disulfide bridges over diselenide bridges to form covalent crosslinks in polypeptides. To this end, our findings warrant a cautious approach towards exploring selenopeptides as drug leads. However, this does not preclude the added value of selenocysteine in the chemical synthesis of cysteine-rich peptides, as well as in manipulating oxidative folding pathways.<sup>[26]</sup>

Our work shows that incorporation of diselenides into conotoxins may significantly improve their folding rates because the oxidative folding of the peptide is catalyzed by the peptide itself. In combination with previous reports, in which diselenides showed superior effects on simplifying and improving folding yields and disulfide mapping, this approach provides a significant advantage to chemical syntheses of cysteine-rich peptides. Since molecular biology techniques have already revealed thousands of bioactive peptides from plants, snails, spiders, scorpions, and vertebrate animals, selenopeptide technologies will accelerate discoveries of novel research tools and biotherapeutics based on cysteine-rich peptides.

## Experimental Section

Detailed methods are provided in the Supporting Information. Briefly, peptides were synthesized with standard Fmoc chemistry; all cysteine residues were trityl protected, and all selenocysteine residues were 4-methoxybenzyl protected. After cleavage from the resin, selenocysteine-containing peptides were treated with DTT. Peptides were then purified by HPLC prior to oxidative folding.

Unless otherwise indicated, all oxidations were air-mediated, using molecular oxygen as the only oxidant. Dried, reduced peptides were redissolved in 5% acetonitrile, 0.01% TFA. The peptide solution was then added to the folding mixture, which contained (final) 0.1M Tris, pH 7.5, 0.1 mM EDTA, as well as any other folding additives for the specific condition. Folding reactions proceeded at 20°C. Timepoints were analyzed by analytical HPLC.



HPLC peak integration was used to quantify the extent of peptide folding for each timepoint. DynaFit was used to derive kinetic parameters by fitting the data to a model of consecutive irreversible first-order reactions.<sup>[24]</sup> Details of the kinetic analysis are presented in the Supporting Information.

Received: January 4, 2012

Revised: March 3, 2012

Published online: March 27, 2012

**Keywords:** kinetics · oxidation · oxygen · protein folding · selenium

- [1] H. Nakamoto, J. C. Bardwell, *Biochim. Biophys. Acta Mol. Cell Res.* **2004**, 1694, 111.
- [2] L. Ellgaard, L. W. Ruddock, *EMBO Rep.* **2005**, 6, 28.
- [3] I. Annis, B. Hargittai, G. Barany, *Methods Enzymol.* **1997**, 289, 198.
- [4] A. M. Steiner, G. Bulaj, *J. Pept. Sci.* **2011**, 17, 1.
- [5] C. Allmang, L. Wurth, A. Krol, *Biochim. Biophys. Acta Gen. Subj.* **2009**, 1790, 1415.
- [6] S. Fiori, S. Pegoraro, S. Rudolph-Böhner, J. Cramer, L. Moroder, *Biopolymers* **2000**, 53, 550.
- [7] C. J. Armishaw, N. L. Daly, S. T. Nevin, D. J. Adams, D. J. Craik, P. F. Alewood, *J. Biol. Chem.* **2006**, 281, 14136.
- [8] K. H. Gowd, V. Yarotsky, K. S. Elmslie, J. J. Skalicky, B. M. Olivera, G. Bulaj, *Biochemistry* **2010**, 49, 2741.
- [9] A. Walewska, A. Jaskiewicz, G. Bulaj, K. Rolka, *Chem. Biol. Drug Des.* **2011**, 77, 93.
- [10] S. Pegoraro, S. Fiori, J. Cramer, S. Rudolph-Böhner, L. Moroder, *Protein Sci.* **1999**, 8, 1605.
- [11] M. Muttenthaler, S. T. Nevin, A. A. Grishin, S. T. Ngo, P. T. Choy, N. L. Daly, S. H. Hu, C. J. Armishaw, C. I. Wang, R. J. Lewis, J. L. Martin, P. G. Noakes, D. J. Craik, D. J. Adams, P. F. Alewood, *J. Am. Chem. Soc.* **2010**, 132, 3514.
- [12] A. Walewska, M. M. Zhang, J. J. Skalicky, D. Yoshikami, B. M. Olivera, G. Bulaj, *Angew. Chem.* **2009**, 121, 2255; *Angew. Chem. Int. Ed.* **2009**, 48, 2221.
- [13] T. S. Han, M. M. Zhang, K. H. Gowd, A. Walewska, D. Yoshikami, B. M. Olivera, G. Bulaj, *ACS Med. Chem. Lett.* **2010**, 1, 140.
- [14] M. Mobli, A. D. de Araújo, L. K. Lambert, G. K. Pierens, M. J. Windley, G. M. Nicholson, P. F. Alewood, G. F. King, *Angew. Chem.* **2009**, 121, 9476; *Angew. Chem. Int. Ed.* **2009**, 48, 9312.
- [15] J. Beld, K. J. Woycechowsky, D. Hilvert, *Biochemistry* **2007**, 46, 5382.
- [16] J. Beld, K. J. Woycechowsky, D. Hilvert, *J. Biotechnol.* **2010**, 150, 481.
- [17] R. S. Norton, B. M. Olivera, *Toxicon* **2006**, 48, 780.
- [18] T. S. Han, M. M. Zhang, A. Walewska, P. Gruszczynski, C. R. Robertson, T. E. Cheatham, D. Yoshikami, B. M. Olivera, G. Bulaj, *ChemMedChem* **2009**, 4, 406.
- [19] A. D. de Araujo, B. Callaghan, S. T. Nevin, N. L. Daly, D. J. Craik, M. Moretta, G. Hopping, M. J. Christie, D. J. Adams, P. F. Alewood, *Angew. Chem.* **2011**, 123, 6657; *Angew. Chem. Int. Ed.* **2011**, 50, 6527.
- [20] A. V. Kachur, C. J. Koch, J. E. Biaglow, *Free Radical Res.* **1999**, 31, 23.
- [21] J. Beld, K. J. Woycechowsky, D. Hilvert, *Biochemistry* **2008**, 47, 6985.
- [22] G. T. Mullenbach, A. Tabrizi, B. D. Irvine, G. I. Bell, R. A. Hallewell, *Nucleic Acids Res.* **1987**, 15, 5484.
- [23] K. H. Gowd, K. Blaise, K. S. Elmslie, A. M. Steiner, B. M. Olivera, G. Bulaj, *Biopolymers (Pept. Sci.)*, DOI: 10.1002/bip.22047.
- [24] M. Muttenthaler, A. Andersson, A. D. Araujo, Z. Dekan, R. J. Lewis, P. F. Alewood, *J. Med. Chem.* **2010**, 53, 8585.
- [25] N. Metanis, D. Hilvert, *Angew. Chem.* **2012**, 124, DOI: 10.1002/ange.201109129; *Angew. Chem. Int. Ed.* **2012**, 51, DOI: 10.1002/anie.201109129.
- [26] C. G. Swain, *J. Am. Chem. Soc.* **1944**, 66, 1696.